Fairfield Bush & CO. grew its stake in shares of Amgen, Inc. (NASDAQ:AMGN) by 0.8% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 33,934 shares of the medical research company’s stock after acquiring an additional 260 shares during the quarter. Amgen comprises about 1.8% of Fairfield Bush & CO.’s holdings, making the stock its 16th largest position. Fairfield Bush & CO.’s holdings in Amgen were worth $6,264,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds and other institutional investors also recently bought and sold shares of AMGN. Pillar Pacific Capital Management LLC boosted its holdings in Amgen by 0.5% in the 2nd quarter. Pillar Pacific Capital Management LLC now owns 56,671 shares of the medical research company’s stock worth $10,461,000 after acquiring an additional 254 shares during the period. Advisors Capital Management LLC boosted its holdings in Amgen by 5.8% in the 2nd quarter. Advisors Capital Management LLC now owns 4,737 shares of the medical research company’s stock worth $874,000 after acquiring an additional 261 shares during the period. Highland Capital Management LLC boosted its holdings in Amgen by 1.0% in the 2nd quarter. Highland Capital Management LLC now owns 27,457 shares of the medical research company’s stock worth $5,068,000 after acquiring an additional 262 shares during the period. Mutual Advisors LLC boosted its holdings in Amgen by 5.8% in the 2nd quarter. Mutual Advisors LLC now owns 4,814 shares of the medical research company’s stock worth $889,000 after acquiring an additional 265 shares during the period. Finally, Reilly Herbert Faulkner III boosted its holdings in Amgen by 0.9% in the 2nd quarter. Reilly Herbert Faulkner III now owns 29,545 shares of the medical research company’s stock worth $5,454,000 after acquiring an additional 268 shares during the period. 82.48% of the stock is owned by institutional investors.
In other news, EVP Sean E. Harper sold 1,525 shares of the stock in a transaction on Monday, July 16th. The stock was sold at an average price of $195.71, for a total value of $298,457.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.27% of the company’s stock.
Several equities analysts have recently commented on the company. Zacks Investment Research upgraded Amgen from a “hold” rating to a “buy” rating and set a $234.00 target price for the company in a research note on Monday, October 1st. Citigroup increased their target price on Amgen from $188.00 to $200.00 and gave the company a “neutral” rating in a research note on Monday, July 30th. Robert W. Baird increased their target price on Amgen from $165.00 to $179.00 and gave the company a “neutral” rating in a research note on Monday, July 30th. Mizuho reiterated a “buy” rating and set a $200.00 target price on shares of Amgen in a research note on Friday, June 22nd. Finally, Goldman Sachs Group reiterated a “buy” rating and set a $228.00 target price on shares of Amgen in a research note on Friday, July 27th. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating and eleven have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $204.90.
NASDAQ AMGN traded up $3.54 during trading hours on Friday, hitting $197.39. The company had a trading volume of 2,784,524 shares, compared to its average volume of 3,571,043. Amgen, Inc. has a fifty-two week low of $163.31 and a fifty-two week high of $210.19. The firm has a market capitalization of $134.17 billion, a PE ratio of 15.69, a P/E/G ratio of 2.02 and a beta of 1.40. The company has a debt-to-equity ratio of 2.03, a current ratio of 3.39 and a quick ratio of 3.12.
Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Thursday, July 26th. The medical research company reported $3.83 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $3.52 by $0.31. Amgen had a return on equity of 43.18% and a net margin of 10.19%. The company had revenue of $6.06 billion during the quarter, compared to analysts’ expectations of $5.73 billion. During the same quarter in the prior year, the business posted $3.27 earnings per share. The company’s revenue for the quarter was up 4.3% compared to the same quarter last year. Equities research analysts expect that Amgen, Inc. will post 13.96 earnings per share for the current fiscal year.
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.
Recommended Story: How a Put Option Works
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.